Repare Therapeutics (RPTX) Stock Forecast, Price Target & Predictions
RPTX Stock Forecast
Repare Therapeutics stock forecast is as follows: an average price target of $18.33 (represents a 457.14% upside from RPTX’s last price of $3.29) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RPTX Price Target
The average price target for Repare Therapeutics (RPTX) is $18.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $10.00. This represents a potential 457.14% upside from RPTX's last price of $3.29.
RPTX Analyst Ratings
According to 5 Wall Street analysts, Repare Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RPTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Repare Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Robert Burns | H.C. Wainwright | $10.00 | $2.81 | 255.87% | 203.95% |
| Feb 03, 2023 | - | Morgan Stanley | $15.00 | $13.14 | 14.16% | 355.93% |
| Nov 17, 2022 | - | H.C. Wainwright | $25.00 | $17.00 | 47.06% | 659.88% |
| Jun 20, 2022 | Joseph Catanzaro | Piper Sandler | $30.00 | $13.27 | 126.07% | 811.85% |
The latest Repare Therapeutics stock forecast, released on Sep 04, 2024 by Robert Burns from H.C. Wainwright, set a price target of $10.00, which represents a 255.87% increase from the stock price at the time of the forecast ($2.81), and a 203.95% increase from RPTX last price ($3.29).
Repare Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $10.00 | $10.00 | $10.00 |
| Last Closing Price | $3.29 | $3.29 | $3.29 |
| Upside/Downside | 203.95% | 203.95% | 203.95% |
In the current month, the average price target of Repare Therapeutics stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 203.95% increase as opposed to Repare Therapeutics's last price of $3.29. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 09, 2023 | Daiwa | - | Buy | Upgrade |
| Feb 03, 2023 | Morgan Stanley | - | Equal-Weight | Downgrade |
| Jun 20, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 02, 2022 | Roth Capital | - | Buy | Initialise |
Repare Therapeutics's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave RPTX a "Overweight" rating, the same as its previous rate.
Repare Therapeutics Financial Forecast
Repare Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $5.68M | $18.20M | $112.55M | - | $408.00K | $6.88M | $278.00K | $279.00K | $166.00K | $135.00K | - |
| Avg Forecast | $3.90M | $3.90M | $3.90M | $3.90M | $3.20M | $2.91M | $2.92M | $38.40M | $18.93M | $6.31M | $7.01M | $5.14M | $9.72M | $1.98M | $5.43M | $2.35M | $3.82M | $244.75K | $1.00M | $1.25M | $2.50M | $1.25M |
| High Forecast | $3.90M | $3.90M | $3.90M | $3.90M | $3.20M | $6.14M | $2.92M | $38.40M | $65.40M | $6.31M | $7.01M | $5.14M | $9.72M | $1.98M | $5.43M | $5.66M | $9.20M | $589.21K | $2.41M | $3.01M | $6.02M | $3.01M |
| Low Forecast | $3.90M | $3.90M | $3.90M | $3.90M | $3.20M | $1.01M | $2.92M | $38.40M | $2.97M | $6.31M | $7.01M | $5.14M | $9.72M | $1.98M | $5.43M | $622.12K | $1.01M | $64.75K | $264.55K | $330.69K | $661.38K | $330.69K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.87% | 56.98% | - | 0.17% | 1.80% | 1.14% | 0.28% | 0.13% | 0.05% | - |
Repare Therapeutics's average Quarter revenue forecast for Jun 23 based on 4 analysts is $7.01M, with a low forecast of $7.01M, and a high forecast of $7.01M. RPTX's average Quarter revenue forecast represents a 23.53% increase compared to the company's last Quarter revenue of $5.68M (Mar 23).
Repare Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-38.42M | $-12.26M | $-34.63M | $-19.23M | $73.76M | - | $-34.30M | $-28.23M | $-31.18M | $-26.28M | $-21.17M | $-16.45M | $-13.28M |
| Avg Forecast | $-1.68M | $-1.68M | $-1.68M | $-1.68M | $-1.38M | $-1.25M | $-1.26M | $-16.53M | $-8.15M | $-2.72M | $-3.02M | $-2.21M | $-4.18M | $-23.74M | $-2.34M | $-35.40M | $-1.65M | $-25.39M | $-20.39M | $-18.26M | $-1.08M | $-14.54M |
| High Forecast | $-1.68M | $-1.68M | $-1.68M | $-1.68M | $-1.38M | $-435.62K | $-1.26M | $-16.53M | $-1.28M | $-2.72M | $-3.02M | $-2.21M | $-4.18M | $-18.99M | $-2.34M | $-28.32M | $-435.40K | $-20.31M | $-16.31M | $-14.61M | $-284.72K | $-11.63M |
| Low Forecast | $-1.68M | $-1.68M | $-1.68M | $-1.68M | $-1.38M | $-2.64M | $-1.26M | $-16.53M | $-28.15M | $-2.72M | $-3.02M | $-2.21M | $-4.18M | $-28.49M | $-2.34M | $-42.48M | $-3.96M | $-30.47M | $-24.47M | $-21.92M | $-2.59M | $-17.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | 14.14% | 4.06% | 15.63% | 4.60% | -3.11% | - | 0.97% | 17.15% | 1.23% | 1.29% | 1.16% | 15.28% | 0.91% |
3 analysts predict RPTX's average Quarter EBITDA for Dec 22 to be $-4.18M, with a high of $-4.18M and a low of $-4.18M. This is -105.67% lower than Repare Therapeutics's previous annual EBITDA (Sep 22) of $73.76M.
Repare Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-51.48M | $-11.95M | $-34.94M | $-31.66M | $75.46M | - | $-34.76M | $-28.29M | $-30.89M | $-26.31M | $-21.42M | $-15.26M | $-13.75M |
| Avg Forecast | $-41.60M | $-39.69M | $-38.41M | $-37.78M | $-37.41M | $-36.87M | $-36.87M | $666.99K | $-15.22M | $-36.45M | $-34.27M | $-34.32M | $-30.08M | $-23.52M | $-34.28M | $-35.97M | $-31.18M | $-25.15M | $-20.41M | $-18.48M | $-16.69M | $-14.11M |
| High Forecast | $-41.60M | $-39.69M | $-38.41M | $-37.78M | $-37.41M | $-34.20M | $-36.87M | $666.99K | $7.88M | $-36.45M | $-34.27M | $-34.32M | $-30.08M | $-18.82M | $-34.28M | $-28.78M | $-1.37M | $-20.12M | $-16.33M | $-14.78M | $-732.82K | $-11.29M |
| Low Forecast | $-41.60M | $-39.69M | $-38.41M | $-37.78M | $-37.41M | $-38.64M | $-36.87M | $666.99K | $-24.19M | $-36.45M | $-34.27M | $-34.32M | $-30.08M | $-28.22M | $-34.28M | $-43.16M | $-88.24M | $-30.19M | $-24.49M | $-22.17M | $-47.22M | $-16.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.41% | 0.35% | 1.02% | 1.05% | -3.21% | - | 0.97% | 0.91% | 1.23% | 1.29% | 1.16% | 0.91% | 0.97% |
Repare Therapeutics's average Quarter net income forecast for Dec 22 is $-30.08M, with a range of $-30.08M to $-30.08M. RPTX's average Quarter net income forecast represents a -139.87% decrease compared to the company's last Quarter net income of $75.46M (Sep 22).
Repare Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.87M | $8.72M | $8.53M | $7.94M | $7.90M | - | $8.78M | $7.64M | $6.60M | $6.74M | $5.24M | $4.79M | $4.00M |
| Avg Forecast | $87.06M | $87.06M | $87.06M | $87.06M | $71.44M | $65.06M | $65.29M | $857.25M | $422.61M | $140.87M | $156.59M | $114.85M | $216.92M | $44.09M | $121.22M | $52.50M | $85.35M | $5.46M | $22.32M | $27.91M | $55.81M | $27.91M |
| High Forecast | $87.06M | $87.06M | $87.06M | $87.06M | $71.44M | $137.05M | $65.29M | $857.25M | $1.46B | $140.87M | $156.59M | $114.85M | $216.92M | $44.09M | $121.22M | $126.38M | $205.46M | $13.15M | $53.74M | $67.18M | $134.36M | $67.18M |
| Low Forecast | $87.06M | $87.06M | $87.06M | $87.06M | $71.44M | $22.59M | $65.29M | $857.25M | $66.36M | $140.87M | $156.59M | $114.85M | $216.92M | $44.09M | $121.22M | $13.89M | $22.58M | $1.45M | $5.91M | $7.38M | $14.76M | $7.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.06% | 0.06% | 0.07% | 0.04% | 0.18% | - | 0.17% | 0.09% | 1.21% | 0.30% | 0.19% | 0.09% | 0.14% |
Repare Therapeutics's average Quarter SG&A projection for Dec 23 is $422.61M, based on 5 Wall Street analysts, with a range of $66.36M to $1.46B. The forecast indicates a 5271.22% rise compared to RPTX last annual SG&A of $7.87M (Sep 23).
Repare Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.22 | $-0.28 | $-0.83 | $-0.76 | $1.80 | - | $-0.83 | $-0.70 | $-0.83 | $-0.71 | $-0.58 | $-0.41 | $-0.37 |
| Avg Forecast | $-0.98 | $-0.94 | $-0.91 | $-0.89 | $-0.88 | $-0.87 | $-0.87 | $0.02 | $-0.36 | $-0.86 | $-0.81 | $-0.81 | $-0.71 | $0.02 | $-0.78 | $-0.86 | $-0.74 | $-0.71 | $-0.60 | $-0.51 | $-0.40 | $-0.38 |
| High Forecast | $-0.98 | $-0.94 | $-0.91 | $-0.89 | $-0.88 | $-0.81 | $-0.87 | $0.02 | $0.19 | $-0.86 | $-0.81 | $-0.81 | $-0.71 | $0.02 | $-0.78 | $-0.04 | $-0.03 | $-0.03 | $-0.03 | $-0.02 | $-0.02 | $-0.02 |
| Low Forecast | $-0.98 | $-0.94 | $-0.91 | $-0.89 | $-0.88 | $-0.91 | $-0.87 | $0.02 | $-0.57 | $-0.86 | $-0.81 | $-0.81 | $-0.71 | $0.02 | $-0.78 | $-2.42 | $-2.09 | $-2.01 | $-1.71 | $-1.43 | $-1.12 | $-1.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.42% | 0.35% | 1.03% | 1.07% | 84.00% | - | 0.97% | 0.95% | 1.17% | 1.17% | 1.15% | 1.04% | 0.98% |
According to 3 Wall Street analysts, Repare Therapeutics's projected average Quarter EPS for Dec 22 is $-0.71, with a low estimate of $-0.71 and a high estimate of $-0.71. This represents a -139.38% decrease compared to RPTX previous annual EPS of $1.80 (Sep 22).
Repare Therapeutics Peer Comparison by Price Target
RPTX Forecast FAQ
Is Repare Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Repare Therapeutics (RPTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of RPTX's total ratings.
What is RPTX's price target?
Repare Therapeutics (RPTX) average price target is $18.33 with a range of $10 to $30, implying a 457.14% from its last price of $3.29. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Repare Therapeutics stock go up soon?
According to Wall Street analysts' prediction for RPTX stock, the company can go up by 457.14% (from the last price of $3.29 to the average price target of $18.33), up by 811.85% based on the highest stock price target, and up by 203.95% based on the lowest stock price target.
Can Repare Therapeutics stock reach $5?
RPTX's average twelve months analyst stock price target of $18.33 supports the claim that Repare Therapeutics can reach $5 in the near future.
What is Repare Therapeutics's current price target trend?
1 Wall Street analyst forecast a $10 price target for Repare Therapeutics (RPTX) this month, up 203.95% from its last price of $3.29. Compared to the last 3 and 12 months, the average price target increased by 203.95% and increased by 203.95%, respectively.
What are Repare Therapeutics's analysts' financial forecasts?
Repare Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $47.44M (high $50.66M, low $45.54M), average EBITDA is $-20.422M (high $-19.604M, low $-21.811M), average net income is $-110M (high $-108M, low $-112M), average SG&A $1.06B (high $1.13B, low $1.02B), and average EPS is $-2.603 (high $-2.54, low $-2.645). RPTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $15.6M (high $15.6M, low $15.6M), average EBITDA is $-6.716M (high $-6.716M, low $-6.716M), average net income is $-157M (high $-157M, low $-157M), average SG&A $348.26M (high $348.26M, low $348.26M), and average EPS is $-3.71 (high $-3.71, low $-3.71).
Did the RPTX's actual financial results beat the analysts' financial forecasts?
Based on Repare Therapeutics's last annual report (Dec 2022), the company's revenue was $131.83M, beating the average analysts forecast of $19.47M by 576.98%. Apple's EBITDA was $-20.104M, missing the average prediction of $-65.661M by -69.38%. The company's net income was $-29.047M, missing the average estimation of $-124M by -76.55%. Apple's SG&A was $32.56M, missing the average forecast of $434.72M by -92.51%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-2.322 by -70.28%. In terms of the last quarterly report (Mar 2023), Repare Therapeutics's revenue was $5.68M, beating the average analysts' forecast of $5.14M by 10.37%. The company's EBITDA was $-34.625M, beating the average prediction of $-2.215M by 1463.41%. Repare Therapeutics's net income was $-34.941M, beating the average estimation of $-34.32M by 1.81%. The company's SG&A was $8.53M, missing the average forecast of $114.85M by -92.57%. Lastly, the company's EPS was $-0.83, beating the average prediction of $-0.809 by 2.65%